Related Experiment Video

Updated: Nov 10, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K

Stereotactic radiotherapy and oligometastases - Authors' reply

Anastasia Chalkidou1, Hannah Patrick2, Matthew Q Hatton3

  • 1King's Technology Evaluation Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EU, UK.

The Lancet. Oncology
|April 1, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.0K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.4K

Related Experiment Videos

Last Updated: Nov 10, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.0K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.4K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial.

EBioMedicine·2026

Personalising radiotherapy dose in anal cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

European urology·2026

Pre-operative proton versus photon-based chemoradiotherapy as an addition to best systemic therapy in the management of oesophageal cancer: protocol for the UK multi-centre randomised phase 2 PROTIEUS study.

BMC cancer·2026

PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.

Clinical and translational radiation oncology·2026

Two-Year Outcomes of the SPARC Phase II Trial: Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Prostate Cancer.

International journal of radiation oncology, biology, physics·2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Normal tissue complication probability modeling of radiation-induced neck fibrosis in head and neck Cancer survivors: a patient-reported outcome-based analysis.

Clinical and translational radiation oncology·2026

Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol.

Clinical and translational radiation oncology·2026

Keratinocytes exposed to ultraviolet A and ultraviolet B radiation induce responses in melanocytes.

Photochemistry and photobiology·2026

Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration.

Rheumatology (Oxford, England)·2026

Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review.

Medicine·2026

hnRNPC facilitates coronavirus replication by directly binding the frameshift-stimulatory element of viral genomic RNA.

PLoS pathogens·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us